UNSPSC 51411906: Droprenilamine hydrochloride

This classification denotes a vasodilating agent C24H33N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OG73JS161X, chemically known as benzenepropanamine, n-(2-cyclohexyl-1-methylethyl)-.gamma.-phenyl-, hydrochloride (1:1), but more generally known as droprenilamine hydrochloride, which bears US NIH Compound Identifier 65471. Most nations, for tariff and trade purposes, schedule droprenilamine hydrochloride under HS 29214980 and SITC 51454.

As of Q4 2014, DROPRENILAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCCCC1)NCCC(C2CCCCC2)C3CCCCC3.CL.

UNSPSC 51411906 Droprenilamine hydrochloride is a Commodity code that encompasses specific pharmaceutical products purchased by state and local governments for emergency medical services and pharmacy benefit programs. Recent solicitations show state and local buyers acquiring advanced life support medications, including droprenilamine and related cardiac and hemodynamic agents, for use in prehospital care and hospital formularies. The issuing bodies include city fire rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. Work under this code ranges from direct procurement of emergency medications by municipal fire departments to broader pharmaceutical supply agreements managed through state cooperative purchasing vehicles that serve multiple jurisdictions and public facilities.

Activity appears concentrated in Texas and Florida, with multistate cooperative purchasing extending across participating states including Minnesota and Oregon. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (response deadline April 8, 2026), soliciting 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus optional renewals. The Texas Health and Human Services Commission issued RFI HHS0017013 (response deadline April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, with contract effectiveness July 1, 2026, and a two-year initial term. The Tampa solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation.